Unknown

Dataset Information

0

Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.


ABSTRACT: BACKGROUND:Although combination antiretroviral therapy (cART) including tenofovir (TDF)+lamivudine (3TC) or emtricitabine (FTC) is recommended for treatment of HIV/HBV coinfected patients, TDF is unavailable in some resource-limited areas. Some data suggest that 3TC monotherapy-based cART may be effective in patients with low pretreatment HBV DNA. METHODS:Prospective study of 151 Chinese HIV/HBV coinfected subjects of whom 60 received 3TC-based cART and 91 received TDF+3TC-based cART. Factors associated with HBV DNA suppression at 24 and 48 weeks, including anti-HBV drugs, baseline HBV DNA, and baseline CD4 cell count, were evaluated overall and stratified by baseline HBV DNA using Poisson regression with a robust error variance. RESULTS:Baseline HBV DNA ?20,000 IU/mL was present in 48.3% and 44.0% of subjects in the 3TC and TDF groups, respectively (P = 0.60). After 48 weeks of treatment, HBV DNA suppression rates were similar between these 2 groups (96.8% vs. 98.0% for 3TC and TDF+3TC, P > 0.999) in subjects with baseline HBV DNA <20,000 IU/mL; whereas in those with baseline HBV DNA ?20,000 IU/mL, TDF+3TC was associated with higher suppression rates (34.5% vs. 72.5% in 3TC and TDF+3TC groups, respectively, P = 0.002). In stratified multivariate regression, TDF use (RR 1.98, P = 0.010) and baseline HBV DNA (per 1 log increase in International Units Per Milliliter, RR 0.74, P < 0.001) were associated with HBV DNA suppression only when baseline HBV DNA ?20,000 IU/mL. CONCLUSION:This study suggests that 3TC monotherapy-based cART is efficacious for HBV treatment through 48 weeks in HIV/HBV coinfection when baseline HBV DNA <20,000 IU/mL. Studies with long-term follow-up are warranted to determine if this finding persists.

SUBMITTER: Li Y 

PROVIDER: S-EPMC4977191 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.

Li Yijia Y   Xie Jing J   Han Yang Y   Wang Huanling H   Zhu Ting T   Wang Nidan N   Lv Wei W   Guo Fuping F   Qiu Zhifeng Z   Li Yanling Y   Du Shanshan S   Song Xiaojing X   Thio Chloe L CL   Li Taisheng T  

Journal of acquired immune deficiency syndromes (1999) 20160501 1


<h4>Background</h4>Although combination antiretroviral therapy (cART) including tenofovir (TDF)+lamivudine (3TC) or emtricitabine (FTC) is recommended for treatment of HIV/HBV coinfected patients, TDF is unavailable in some resource-limited areas. Some data suggest that 3TC monotherapy-based cART may be effective in patients with low pretreatment HBV DNA.<h4>Methods</h4>Prospective study of 151 Chinese HIV/HBV coinfected subjects of whom 60 received 3TC-based cART and 91 received TDF+3TC-based c  ...[more]

Similar Datasets

| S-EPMC6130076 | biostudies-literature
| S-EPMC5573866 | biostudies-literature
| S-EPMC4543549 | biostudies-literature
2005-10-01 | GSE3049 | GEO
| S-EPMC4335865 | biostudies-literature
| S-EPMC5028254 | biostudies-literature
| S-EPMC7308798 | biostudies-literature
| S-EPMC3292846 | biostudies-literature
| S-EPMC3539467 | biostudies-literature
| S-EPMC8107265 | biostudies-literature